Hot Features
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also de... Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1 | 2.50626566416 | 3.99 | 4.61 | 3.9 | 68903 | 4.11471853 | CS |
| 4 | -0.28 | -6.40732265446 | 4.37 | 5.01 | 3.9 | 84157 | 4.328379 | CS |
| 12 | -1.32 | -24.3992606285 | 5.41 | 5.89 | 3.8 | 79912 | 4.46882807 | CS |
| 26 | 0.56 | 15.8640226629 | 3.53 | 7.75 | 3.3 | 156269 | 5.56698672 | CS |
| 52 | 2.16 | 111.917098446 | 1.93 | 7.75 | 1.305 | 299062 | 3.45131802 | CS |
| 156 | 2.01 | 96.6346153846 | 2.08 | 12.3 | 0.1349 | 283062 | 2.11130485 | CS |
| 260 | -9.9 | -70.7648320229 | 13.99 | 14.44 | 0.1349 | 294436 | 3.69692724 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.